TARGIT-IORT during lumpectomy for breast cancer - better for patients than other PBI approaches

Jayant S. Vaidya, MD PhD, Max Bulsara, PhD, Elena Sperk, MD, Samuele Massarut, MD, Michael Douek, MD, Michael Alvarado, MD, Steffi Pigorsch, Dennis Holmes, MD, Marcelle Bernstein, Christobel Saunders, MD, Henrik Flyger, MD, David Joseph, MD, Frederik Wenz, MD, Jeffrey S. Tobias, MD, on behalf of the TARGIT-A investigators

PII: S0360-3016(21)00199-1
DOI: https://doi.org/10.1016/j.ijrobp.2021.01.059
Reference: ROB 26913

To appear in: International Journal of Radiation Oncology • Biology • Physics

Received Date: 26 January 2021
Accepted Date: 26 January 2021


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Elsevier Inc. All rights reserved.
TARGIT-IORT during lumpectomy for breast cancer - better for patients than other PBI approaches

Jayant S. Vaidya1 MD PhD, Max Bulsara2 PhD, Elena Sperk3 MD, Samuele Massarut4 MD, Michael Douek5 MD, Michael Alvarado6 MD, Steffi Pigorsch7, Dennis Holmes8 MD, Marcella Bernstein9, Christobel Saunders10 MD, Henrik Flyger11 MD, David Joseph12 MD, Frederik Wenz13 MD, Jeffrey S. Tobias14 MD on behalf of the TARGIT-A investigators

1. Division of Surgery and Interventional Science, University College London, 43-45 Foley Street, London W1W 7JN, UK
2. Department of Biostatistics, University of Notre Dame, Fremantle, WA, Australia
3. Department of Radiation Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg, University, Heidelberg, Germany
4. Department of Surgery, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
5. The Department of Surgical Sciences, University of Oxford, Oxford, UK
6. Department of Surgery, University of California, San Francisco, CA, USA
7. Department of Gynaecology and Obstetrics, Red Cross Hospital, Technical University of Munich, Munich, Germany
8. University of Southern California, John Wayne Cancer Institute & Helen Rey Breast Cancer Foundation, Los Angeles, CA School of Surgery, University of Western Australia, Crawley, WA, Australia
9. Patient advocate, London, UK
10. School of Surgery, University of Western Australia, Crawley, WA, Australia
11. Department of Breast Surgery, University of Copenhagen, Copenhagen, Denmark
12. Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia
13. University of Frieberg, Frieberg, Germany
14. Department of Clinical Oncology, University College London Hospitals, London, UK

Corresponding Author: Professor Jayant S Vaidya jayantvaidya@gmail.com

Author Responsible for Statistical Analysis: Professor Max Bulsara max.bulsara@nd.edu.au

Conflict of Interest Statement for All Authors – uploaded forms

Funding Statement: There was no specific funding for this work. The TARGIT-A trial was initiated by an academic insight and collaboration with the industry was solely for the development of the device. The manufacturers of the Intrabeam device (Carl Zeiss) did not have any part in concept, design, or management of the trial, or in data analysis, data interpretation, or writing of the report. The study was sponsored by University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre. Funding was provided by UCLH Charities, National Institute for Health Research (NIHR) Health Technology Assessment programme (HTA 07/60/49), Ninewells Cancer Campaign, National Health and Medical Research Council, and German Federal Ministry of Education and Research (BMBF) FKZ 01ZP0508. The infrastructure of the trial operations office in London, UK was supported by core funding from Cancer Research Campaign (now Cancer Research UK) when the trial was initiated. The funding organisations had no role in concept, design, analysis or writing of the manuscript.

[Data Availability Statement for this Work] – Not applicable

[Acknowledgements] – not specifically for this work
Dear Sir,

The authors of the Budapest randomised trial\textsuperscript{1} of partial breast irradiation (PBI) recruited a very low-risk patients (T1N0, Grade 1 or 2). Their small sample size (n=258) was a little more than $1/10^{th}$ of the TARGIT-A randomised trial (n=2298) published in the BMJ\textsuperscript{2}. Yet they fail to mention it. TARGIT-A compared risk-adapted single-dose targeted intraoperative radiotherapy (TARGIT-IORT) \textit{during lumpectomy} vs whole breast radiotherapy (EBRT). TARGIT-IORT achieved comparable long-term outcomes to EBRT for local control, distant control, breast preservation and breast-cancer mortality, along with a significant and substantial reduction in non-breast-cancer mortality by 4.4% by 12 years (5.41% vs 9.85%, p=0.005). With this magnitude of survival benefit, a new cytotoxic agent would achieve high-profile rapid adoption!

They also fail to correctly cite the trial of delayed IORT (n=1153) reported in JAMA Oncology\textsuperscript{3,4}. Instead, they selectively refer to the hypothetical and erroneous statistics from a correspondence letter, without noting our robust rebuttal\textsuperscript{3,4} - their fundamental error was not recognising that TARGIT-A was a non-inferiority trial. The median follow-up was 9 years (they wrongly state 5 years, and give an incorrect p-value in Table 4). They overlook that the 10-year local recurrence-free survival was not statistically different (80.16% vs 84.36%, p=0.052), and mastectomy-free survival was virtually identical (83.79% vs 83.82%, p=0.38). We repeatedly stress our strong preference for TARGIT-IORT \textit{during} the initial lumpectomy\textsuperscript{2-4}.

Then they fall prey to the temptation of comparing TARGIT-A with the PRIME-II trial of ‘no-radiotherapy’ vs EBRT. Unlike the wide eligibility for TARGIT-A (≥ 45 years, ≤3.5cm invasive ductal carcinoma), PRIME-II recruited only ultra-low risk patients ≥ 65 years. In fact, three-quarters of the TARGIT-A patients\textsuperscript{2} \textit{would not have been eligible for the PRIME-II trial} because they were either too young or had node positive (22%), grade 3 (20%) or ER/PR negative (19%) disease! Yet, even in this ultra-low risk PRIME-II trial, the reduction in local control in the absence of radiotherapy was dramatic, with a local recurrence of 9.8% vs 0.9% at 10 years (SABCS 2020 https://www.abstractsonline.com/pp8/#/19223/presentation/579). PRIME-II found no hint of a reduction in mortality- the benefit of avoiding radiation was perhaps nullified by the harm from the large increase in local relapse. On the other hand, when TARGIT-IORT is given during lumpectomy (higher-risk patients, much larger trial), there is no reduction in the patient’s chance of being free of local recurrence, preserving the breast, or
Survival from breast cancer, and there is a substantial reduction in deaths from cardiovascular causes and other cancers.

PBI whether with brachytherapy wires/balloon or external beam, is very cumbersome to patients, requiring several hospital visits or even an in-patient stay\(^5\). These approaches inevitably deliver significant scattered irradiation to the nearby organs at risk (OARs) such as the heart and the lung\(^6\). TARGIT-IORT involves much less travel, delivers the least dose to OARs, has reduced toxicity, less pain and improves quality of life and cosmetic outcome\(^2\,\^\,\,^6\,\,^7\). To quote many patients, single-dose TARGIT-IORT delivered during surgery is a “no-brainer”.

The elephant in the room is something we have naively touted as an advantage: TARGIT-IORT is a high-value treatment, saving substantial sums (e.g. $1.5 billion over 5 years in the US\(^8\,\,^9\)) to the healthcare system. However, from the perspective of the healthcare provider, these savings result in a substantially lower income-stream for the department or the individual, compared with any other method of radiotherapy. These considerations may reverse with the introduction of a value-based system for remuneration.

As an editorial in this journal pointed out\(^10\), “Many careers have been built around fractionated radiation therapy for breast cancer, and it comprises a substantial proportion of the practice of the average contemporary radiation oncologist. Depending on your perspective, intraoperative radiation therapy is thus either a very serious threat or a quantum leap forward.”.

260 centres in 38 countries worldwide have already treated 45,000 patients with TARGIT-IORT, which is now included in several national and international guidelines (https://targit.org.uk/targit-iort-in-guidelines).
References


